Molecular Templates, Inc. (NASDAQ:MTEM – Get Rating) Director Kevin M. Lalande acquired 62,000 shares of the firm’s stock in a transaction dated Wednesday, June 15th. The stock was bought at an average price of $0.89 per share, with a total value of $55,180.00. Following the acquisition, the director now directly owns 222,000 shares in the company, valued at $197,580. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Shares of NASDAQ:MTEM opened at $0.88 on Thursday. Molecular Templates, Inc. has a 52-week low of $0.76 and a 52-week high of $8.62. The company has a market capitalization of $49.58 million, a P/E ratio of -0.64 and a beta of 1.61. The company has a 50-day simple moving average of $1.34 and a 200 day simple moving average of $2.52. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.94 and a current ratio of 2.94.
Molecular Templates (NASDAQ:MTEM – Get Rating) last issued its quarterly earnings data on Thursday, May 12th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.04. The firm had revenue of $8.49 million during the quarter, compared to the consensus estimate of $6.88 million. Molecular Templates had a negative net margin of 177.06% and a negative return on equity of 110.16%. As a group, equities analysts forecast that Molecular Templates, Inc. will post -1.62 earnings per share for the current year.
Several equities analysts have recently weighed in on the company. Stifel Nicolaus decreased their price objective on Molecular Templates from $11.00 to $9.00 in a report on Friday, May 13th. Barclays cut their target price on shares of Molecular Templates from $8.00 to $4.50 and set an “overweight” rating for the company in a research note on Wednesday, March 30th. Finally, Bank of America downgraded shares of Molecular Templates from a “buy” rating to an “underperform” rating and set a $1.50 target price for the company. in a research note on Friday, May 27th.
Molecular Templates Company Profile (Get Rating)
Molecular Templates, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform.
- Get a free copy of the StockNews.com research report on Molecular Templates (MTEM)
- Downturn Gives These 3 Buys Juicy Dividend Yields
- Victoria’s Secret Stock is Out of the Box
- Time For a Ride in Six Flags Stock
- Why Dollar General (NYSE: DG) Should Be In Your Portfolio
- Korn Ferry Is A Good Buy For The Recession And Beyond
Receive News & Ratings for Molecular Templates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Templates and related companies with MarketBeat.com's FREE daily email newsletter.